Two-Week Efficacy of an Occluding Dentifrice on Dentinal Hypersensitivity
Objectives: To investigate the efficacy of an experimental anhydrous 0.454% w/w stannous fluoride dentifrice in relieving dentinal hypersensitivity (DH) after 7 and 14 days’ brushing compared with a 0.76% w/w sodium monofluorophosphate marketed control dentifrice. Methods: This was a single-center, randomized, examiner-blind, two-treatment arm, stratified, controlled, parallel-design study in otherwise healthy subjects with DH (N=141). Two non-adjacent teeth with DH were selected and tactile threshold (Yeaple probe) and evaporative air sensitivity (Schiff sensitivity score) were assessed at baseline. Subjects brushed twice-daily for at least 1 minute with their assigned dentifrice; those using the Experimental dentifrice also included an initial focused brushing of test teeth. Schiff sensitivity and tactile threshold scores were re-assessed after 7 and 14 days. Results: The Experimental dentifrice reduced DH, as assessed by both Schiff and tactile threshold measures, compared to baseline after 7 and 14 days’ use (all p<.0001). The Control dentifrice had no significant effect on DH at either time-point. The Experimental dentifrice demonstrated a reduction in DH compared to Control for both measures at both time-points (all p<.0001). Study products were generally well-tolerated. Conclusions: The 0.454% stannous fluoride-containing Experimental dentifrice demonstrated statistically significantly greater changes in two indices of DH after both 7 and 14 days’ use than a marketed control dentifrice.
IADR/AADR/CADR General Session
2017 IADR/AADR/CADR General Session (San Francisco, California) San Francisco, California
2017 1544 Oral Health Research
Goyal, C. Ram
( All Sum Research Center Ltd
, Mississauga
, Ontario
, Canada
)
Sufi, Farzana
( GlaxoSmithKline
, Surrey
, United Kingdom
)
Qaqish, Jimmy
( All Sum Research Center Ltd
, Mississauga
, Ontario
, Canada
)
Creeth, Jonathan
( GlaxoSmithKline
, Surrey
, United Kingdom
)
JC and FS are employees of GlaxoSmithKline Consumer Healthcare, which funded
All Sum Research Center Ltd. to perform this study.